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Subjects
Four groups of subjects were studied. First, a group of five Fe-deficient subjects (Table 1) . Women likely to conceive were excluded; none was currently being treated with oral Fe. A second group of subjects was undergoing regular venesection for polycythaemia. They were Fe-deficient, although haemoglobin levels were normal (Table 1) . Healthy volunteers were used as controls.
No subject was studied more than twice (i.e. two preparations). The maximum dose of radioactivity administered to any subject was 147 kBq.
The Fe status of each subject was assessed from the haemoglobin (Hb) level, erythrocyte indices, particularly mean corpuscular haemoglobin (MCH), serum Fe, total Fe-binding capacity, Fe saturation and serum ferritin levels. Hb, MCH, serum Fe, percentage saturation and ferritin levels were combined in each subject to produce an 'Fe deficiency index'. Each marker outside normal ranges scored 1.
Iron absorption
Fe absorption was measured by whole-body counting. The locally constructed shadow shield counter drew the subject at constant speed between two opposed NaI scintillation detectors (125 mm diameter x 50 mm thick) 920 mm apart. An energy window was chosen to optimize the 'figure of merit' and the deleterious effects of potential drift of window size or position. This was 0.6-1.4 MeV, with a sensitivity of 1.6 counts/s (cps) per kBq (59 cps/pCi) with a source of 37 kBq (1 pCi) within 80 mm scatter.
Preliminary studies showed, by serial counting of stools in normal subjects, that almost all unabsorbed "Fe was excreted in the faeces within 3 d of ingestion. Subjects were starved for at least 4 h and then counted before taking the oral Fe dose. This produced the 'background count'. The dose of j9Fe was then taken by mouth, nothing further was taken orally for 2 h, and 2-6 h later another whole-body count was performed under identical conditions. This count minus the background count produced the 'administered dose'. After 7 d the subject was recounted and the 'residual dose' obtained, again correcting for background. The percentage absorption was then calculated, allowing for the decay of 5 9 F e : residual dose administered dose 5sFe absorbed = x decay correction x 100.
After an interval of at least 2 weeks the procedure was repeated with a second Fe preparation.
Fe was administered either as FeSO, or complexes of Fe"+ with the 3-hydroxy-4pyranones maltol or ethyl maltol. These complexes were prepared by adding the hydroxypyranone to an aqueous solution of FeCl, in 1 : 2 or 1 : 3 molar ratios and adjusting the pH to 4.0. Recrystallization from water yielded homogeneous crystals of the 1:3 complex of either Tris maltol Fe3+ or Tris ethylmaltol Fe3+.
E.uper imen ts
Fe absorption was measured in the following experiments with 10 mg Fe and 73 kBq (2 pCi) "Fe. All percentage absorption values are given as means and standard deviations.
(1) Oral solutions of 1 : 3 ferric maltol or FeSO, in either milk (n 2; Fe-deficient) or chicken soup (n 7; two normal, five Fe-deficient; Table 1 ). (2) Oral solutions of I : 3 ferric ethyl maltol or FeSO, in distilled water ( n 5 ; Fe-deficient; Table 1 ). (3) Oral solutions of 1 :2 ferric maltol and FeSO, (n 5; normals; Table 2 ). Maltol and ethyl maltol can combine with Fe3+ in different ratios, namely 1 : 1, 1 :2 and 1 : 3 . Over the pH range 6.0-9.0 the non-charged 1 : 3 complex predominates (Hider & Hall, 1991) , but at the acid pH values in the stomach the positively charged 1 : 2 complex becomes the major form. Ferric maltol or ferric ethyl maltol were mostly given as the 1 : 3 complex, which will dissociate to the 1 :2 complex in the acid lumen of the stomach and may not reform in the duodenum. In order to assess the effects of this dissociation five normal subjects received 1 : 2 ferric maltol solutions, and the absorption of Fe from this preparation was compared with that from a solution of FeSO, (Table 2) .
Results are expressed as means and standard deviations, and the significance of the results was compared by Student's paired two-sided t test on logarithmically transformed dot plots since the data were skewed.
Ethical considerations
Informed written consent was obtained from all subjects and the protocol was approved by the St Thomas' Hospital Ethical Committee and the DHSS Administration of Radioactive Substances Advisory Committee.
R E S U L T S
When FeSO, and ferric maltol were taken with milk or soup, absorption from the two preparations was similar (Table 1) . Thus, the percentage Fe absorption in the Fe-deficient subjects taking soup was 35.4 (SD 22.1) v. 20.6 (SD 9.0) ( P = 0.06) for sulphate and maltol respectively. The efficiency of absorption from water was higher (Table l) , the mean percentage Fe absorption for FeSO, and ferric ethyl maltol reaching 52.0 (SD 17.7) v . 28.7 (SD 11 .3) ( P < 0.05) respectively (Table 2) .
In normal subjects the absorption of Fe from solutions of ferric maltol given as the 1 : 2 complex and from FeSO, solutions was similar (Table 2) .
DISCUSSION
The absorption of Fe from ferric maltol and ferric ethyl maltol was comparable with that from FeSO,, a finding that contrasts markedly with most other Fe3+ preparations (Dietzfelbinger, 1987; Heinrich, 1987) . Absorption from the 1 :2 and 1 :3 complexes was similar. A similar result, in which the rise in serum levels was measured (Crosby & O'Neil-Cutting, 1984) , was obtained in another study using both 10 and 60 mg doses of Fe as ferric maltol (Kelsey et al. 1991) .
As ferric maltol is much less likely than FeSO, to generate hydroxyl radicals, or to bind non-specifically to membrane surfaces or proteins, it is predicted to lack many of the side effects commonly experienced with FeSO, in pharmacological doses. In the present study the Fe complexes were well tolerated and, indeed, one volunteer has taken 360 mg and 720 mg Fe as ferric maltol without side effect. Similarly, because ferric maltol does not generate strong acid on hydrolysis it is less likely than FeSO, to cause acute toxicity in overdose. 
